Skip to main content
颖泰生物 logo

颖泰生物 — Investor Relations & Filings

Ticker · 920819 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 419 across all filing types
Latest filing 2022-08-09 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920819

About 颖泰生物

https://www.nutrichem.cn/

Nutrichem Company Limited focuses on the research, development, production, and distribution of agrochemical active ingredients and formulations. The product portfolio includes a diverse array of herbicides, fungicides, and insecticides tailored for global agricultural applications. The company provides comprehensive contract development and manufacturing organization (CDMO) services, supporting international partners through the entire product lifecycle from synthesis to commercial-scale production. With a strong emphasis on research and development, Nutrichem utilizes advanced chemical synthesis technologies and process optimization to ensure high-quality output and operational efficiency. Its integrated supply chain and large-scale manufacturing infrastructure enable the delivery of customized crop protection solutions to meet the evolving needs of the global agricultural sector.

Recent filings

Filing Released Lang Actions
西南证券股份有限公司关于北京颖泰嘉和生物科技股份有限公司使用闲置募集资金暂时补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a formal opinion from Southwest Securities Co., Ltd. regarding Beijing Yingtai Jiahe Biotechnology Co., Ltd.'s use of idle raised funds to temporarily supplement working capital. It references regulatory guidelines related to the management and use of raised funds, details the amount and usage of funds raised from a public stock issuance, and confirms compliance with relevant laws and company policies. The document includes a verification opinion from the sponsor institution but does not contain financial statements or comprehensive financial data. It is a specialized report on the use of raised funds, essentially an audit or verification opinion on a specific financial compliance matter rather than a full annual or interim report. The document length is about 3,000 characters, which is relatively short and focused on a specific compliance verification. Therefore, it fits best under the category of Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles related to regulatory compliance, excluding full annual reports. H1 2022
2022-08-09 Chinese
使用闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the use of idle raised funds for cash management by Beijing Yingtai Jiahe Biotechnology Co., Ltd. It details the amount of funds raised, their usage, storage, and the decision-making process for investing idle funds in safe financial products. It includes independent director opinions and sponsor institution opinions confirming compliance with regulations. The document is a regulatory announcement about the company's capital management activities related to fundraising proceeds, not a full financial report or earnings release. It does not contain comprehensive financial statements or detailed financial performance data. The document length is 3339 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on the company's fundraising proceeds usage and capital management activities.
2022-08-09 Chinese
西南证券股份有限公司关于北京颖泰嘉和生物科技股份有限公司使用闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is issued by Southwest Securities Co., Ltd. as the sponsor institution for Beijing Yingtai Jiahe Biotechnology Co., Ltd. It provides an opinion on the company's use of idle raised funds for cash management. The document references regulatory rules related to the management and use of raised funds, details the amount and usage of raised funds, and confirms compliance with relevant laws and company rules. It includes a verification opinion from the sponsor institution rather than the company's own financial statements or a full report. The document length is 3650 characters, which is relatively short and focused on a specific verification opinion rather than a full financial report or announcement of voting results. It is not an annual or interim report, earnings release, or capital update. It is a formal verification opinion related to the use of raised funds, which fits best under Regulatory Filings (RNS) as it does not constitute a full audit report or annual report but is a regulatory compliance document.
2022-08-09 Chinese
关于召开2022年第二次临时股东大会通知公告（提供网络投票）
Regulatory Filings Classification · 95% confidence The document is a notice announcing the convening of the 2022 second extraordinary general meeting of shareholders (临时股东大会通知公告). It details the meeting date, voting methods, eligibility, agenda items, registration procedures, and contact information. It does not contain financial statements or detailed financial analysis. It is not a report itself but an announcement about a shareholder meeting. Therefore, it fits the category of a meeting notice or announcement related to shareholder meetings. Among the given categories, the closest match is 'Declaration of Voting Results & Voting Rights Announcements (DVA)' or 'Proxy Solicitation & Information Statement (PSI)'. However, since this document is a notice of the meeting itself rather than voting results or proxy materials, it is best classified as a Regulatory Filing (RNS) as a fallback for miscellaneous regulatory announcements that do not fit other categories. The document length is short (2292 characters), and it is clearly an announcement, not a report or transcript. Hence, the classification is RNS with high confidence.
2022-08-09 Chinese
2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告" which translates to "Half-Year Report" or "Interim Report" for the period 2022. It contains detailed financial data including income, profit, assets, liabilities, and operational performance metrics. The document includes comprehensive sections such as company overview, accounting data, business review, risk factors, and financial statements. It explicitly states the report period as January 1, 2022 to June 30, 2022, which is a period shorter than a full fiscal year. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes actual financial statements and substantive financial data and analysis, not just references or certifications. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-09 Chinese
第三届监事会第十三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Beijing Yingtai Jiahe Biotechnology Co., Ltd. regarding the 13th meeting of the 3rd Supervisory Board. It details the meeting date, attendance, and the approval of several proposals including the 2022 semi-annual report, profit distribution plan, and reports on the use of raised funds. The document references other announcements and reports published on August 10, 2022, but itself is a meeting resolution announcement rather than the reports or financial statements. It is not a full financial report, earnings release, or management report, but rather a formal announcement of meeting decisions and approvals. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement of meeting resolutions and approvals without substantive financial data or full report content.
2022-08-09 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.